Platinum-Resistant Ovarian Cancer: Trial Results at ESMO 2024
Friday, 13 September 2024, 05:56
Trial Overview
In the ongoing pursuit of effective treatments for platinum-resistant ovarian cancer, Ascendis is set to unveil groundbreaking results at ESMO 2024. The Phase 1/2 IL-Believe Trial highlights the efficacy of TransCon IL-2 β/γ. This trial especially focuses on patients who have shown resilience against traditional platinum-based therapies.
Efficacy Results
- 29% of efficacy-evaluable patients exhibited anti-tumor responses.
- A total of 4 out of 14 patients responded positively.
- Combination therapies are showcasing new hope in treatment landscapes.
Clinicians and researchers recognize the potential of this innovative therapy in combating challenging cancer forms, potentially setting new standards in treatment protocols.
This article was prepared using information from open sources in accordance with the principles of Ethical Policy. The editorial team is not responsible for absolute accuracy, as it relies on data from the sources referenced.